Scleroderma and interstitial lung disease: The Lancet Respiratory Medicine: July 25, 2016

Donald Tashkin discusses a clinical trial for the treatment of scleroderma-related interstitial lung disease, a rare but devastating condition. Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv